examined leukemia cells from 40 patients with B-CLL and compared them
with lymphocytes from normal donors. They found that Lyn was markedly
overexpressed in CLL cells and an unusual amount of the enzyme was
found in the cell cytosol. In addition, the enzyme was constantly
active compared with levels of activity in normal donor cells.
The authors went on to show that inhibition of Lyn was able to restore
the process of cell apoptosis to normal and treatment of malignant
cells with drugs that induce cell death decreased both Lyn expression
levels and activity ?suggesting a direct correlation between high Lyn
activity and the ability of these B cells to resist apoptosis. The
authors suggest that Lyn is involved in the development of B-CLL and
that this enzyme therefore represents an attractive target for therapy.
The study will appear online on January 13 in advance of publication in
the February 1 print edition of the Journal of Clinical Investigation.
Source:Journal of Clinical Investigation